

SUPPLEMENTARY MATERIALS

Radiolabelling of 1,4-substituted 3-[¹⁸F]fluoropiperidines and its application to new radiotracers for the NR2B NMDA receptors visualization

Radouane Koudih,^{a,b,c} Gwénaëlle Gilbert,^{a,b,c} Martine Dhilly,^{a,b,c} Ahmed Abbas,^d Louisa Barré,^{a,b,c} Danièle Debruyne^{a,b,c} and Franck Sobrio^{*a,b,c}

^a CEA, I2BM, LDM-TEP, UMR 6302 ISTCT, GIP Cyceron, BP5229, F-14074 Caen, France. Fax: +33 2 3147 0225; Tel: +33 2 3147 0264; E-mail: sobrio@cyceron.fr

^b Université de Caen Basse-Normandie, UMR 6302 ISTCT, LDM-TEP, GIP Cyceron, F-14074 Caen, France

^c CNRS, UMR 6302 ISTCT, LDM-TEP, GIP Cyceron, F-14074 Caen, France

^d INSERM U1077, GIP Cyceron, F-14074 Caen, France

Content

1. Synthetic procedures (3-32)	S2
2. <i>In silico</i> calculated pharmacological properties	S15
3. NMR spectra (4-12 , 18-21 and 29)	S16

1. Synthetic procedures

1.1. Materials and reagents

Reagents and solvents used, unless stated otherwise, were of commercially available reagents grade quality and were used without further purification. Nuclear magnetic resonance spectra ^1H , ^{13}C and ^{19}F NMR were recorded on a Bruker DRX 400, at 400 MHz, 100.6 MHz and 376.4 MHz respectively. ^1H NMR spectra were referenced internally on CDCl_3 (^1H 7.26) and ^{13}C NMR spectra were referenced internally on CDCl_3 (^{13}C 77.20). Coupling constants (J) are expressed in hertz (Hz) and coupling patterns are abbreviated as: s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet), dd (doublet of doublet) and dt (doublet of triplet). IR spectra were recorded on a Thermo Scientific Nicolet 380 FT-IR spectrometer. Flash chromatography purifications were performed on Macherey-Nagel silica gel 60 M (0.04-0.063 mm). Thin Layer Chromatography (TLC) was run on pre-coated aluminium plates of silica gel 60F₂₅₄ (Merck) and Rf were established either using either an UV-lamp at 254 nm either by ninhydrin or phosphomolybdic acid hydrate spray reagent. Radioactive TLC was measured using an Instant Imager® Packard apparatus. Melting points were determined on a Barnstead Electrothermal IA 9100 melting point apparatus and are uncorrected. HPLC analyses were performed using a Waters 600 pump and controller, a Waters 717 plus autosampler and a Waters 996 photodiode arrays detector (210-380 nm) coupled with a NaI probe radioactive detector (Novelec, France). Purity was determined by HPLC on an analytical column CC 250/4 Nucleodur C-18 ISIS, Macherey-Nagel, 5 μm ; 1 mL/min at 220 nm and at 235 nm and the purities of compounds were found to be at least 98%. [^{18}F]-fluoride was produced by the $^{18}\text{O}(\text{p},\text{n})^{18}\text{F}$ nuclear reaction using the Cyclone 18/9 (IBA) cyclotron at the Cyceron PET Center. Irradiation occurred on target filled with ^{18}O -enriched water (97%, Eurisotop).

1.2. (\pm)-*cis*-1-Benzyl-4-(hydroxymethyl)piperidin-3-ol (**4**).

To (\pm)-*cis*-1-benzyl-4-(acetyloxymethyl)piperidin-3-yl acetate^{22,23} (2.1 g, 6.88 mmol) was added NaOH in methanol (40 mL, 2N). The reaction mixture was stirred at room temperature for 15 h, then diluted with brine (40 mL) and extracted with EtOAc (4 x 15 mL). The combined organic layers were dried over MgSO_4 , filtered and concentrated under reduced pressure to give **4** (1.43 g, 94%) as yellow crystals. mp: 81-83°C. ^1H NMR (400 MHz, CDCl_3) δ 7.24-7.19 (m, 5H); 3.86 (s, 1H); 3.59 (d, $^3\text{J}=4.8$ Hz, 2H); 3.44 (s, 2H); 2.89-2.79 (m, 4H); 2.06 (dd, $^2\text{J}=11.6$ Hz, $^3\text{J}=1.2$ Hz, 1H); 1.90 (ddd, $^3\text{J}=3.2$ Hz, $^3\text{J}=12.8$ Hz, $^2\text{J}=12.4$ Hz, 1H); 1.66-1.63 (m, 1H); 1.46-1.35 (m, 2H). ^{13}C NMR (100.6 MHz, CDCl_3) δ 137.9; 129.0; 128.2; 127.1; 67.0; 64.9; 62.6; 59.6; 52.8; 41.3; 22.9. $\nu_{\text{max}}/\text{cm}^{-1}$ 3344, 2920, 1012. HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{13}\text{H}_{20}\text{NO}_2$ 222.1494; found 222.1502.

1.3. (\pm)-*cis*-4-(Hydroxymethyl)piperidin-3-ol (**5**).

To a solution of **4** (2.0 g, 9.04 mmol) in methanol (60 mL), was added palladium (10%) on activated carbon catalyst (500 mg). The reaction mixture was stirred under H_2 atmosphere (1.5 bars) at room temperature for 6 h. The mixture was filtered off then concentrated under reduced pressure to give **5** (1.18 g, 99%) as a white solid. mp: 128-129°C. ^1H NMR (400 MHz, CD_3OD) δ 4.01 (s, 1H); 3.65 (dd, $^3\text{J}=7.2$ Hz, $^2\text{J}=10.8$ Hz, 1H); 3.48 (dd, $^3\text{J}=6$ Hz, $^2\text{J}=10.8$ Hz, 1H); 3.15-3.25 (m, 2H); 2.8 (dd, $^2\text{J}=13.6$ Hz, $^3\text{J}=1.6$ Hz, 1H); 2.70 (ddd, $^3\text{J}=3.6$ Hz, $^3\text{J}=12.8$ Hz, $^2\text{J}=12.8$ Hz, 1H); 1.77-1.66 (m, 2H); 1.55-1.52 (m, 1H). ^{13}C NMR (100.6

MHz, CD₃OD) δ 65.0; 64.7; 52.3; 45.8; 42.8; 23.4. $\nu_{\max}/\text{cm}^{-1}$ 3260, 2859, 1541, 1054. HRMS (ESI, [M+H]⁺) m/z calcd. for C₆H₁₄NO₂ 132.1025; found 132.1031.

1.4. (±)-*cis-tert*-Butyl 1-[4-(hydroxymethyl)piperidin-3-ol-1-yl] carboxylate (6).

To a solution of **5** (837 mg, 6.38 mmol) in DMF (30 mL), was added di-*tert*-butyl dicarbonate (2.78 g, 12.76 mmol). The reaction mixture was stirred for 48h at room temperature, then diluted with brine (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. Purification by silica gel chromatography (CH₂Cl₂ / MeOH, 95:5) gave **6** as a colourless oil (1.18 g, 80%). ¹H NMR (400 MHz, CD₃OD) δ 4.0-3.97 (m, 2H); 3.80 (br s, 1H); 3.52 (ABX, dd, ³J=6.8 Hz, ²J=10.8 Hz, 1H); 3.38 (ABX, dd, ³J=6.4 Hz, ²J=10.8 Hz, 1H); 2.87-2.57 (m, 2H); 1.58-1.56 (m, 1H); 1.48 (dddd, ³J=12.8 Hz, ³J=12.8 Hz, ²J=12.8 Hz, ³J=4.4 Hz, 1H); 1.35-1.32 (m, 10H). ¹³C NMR (100.6 MHz, CD₃OD) δ 156.1; 80.0; 67.3; 65.1; 50.1; 44.0, 41.4; 28.4; 22.4. $\nu_{\max}/\text{cm}^{-1}$ 3383, 2923, 1662, 1365, 1162, 1052. MS (ESI) m/z 232 ([M+H]⁺, 68); 176 (100). HRMS (ESI, [M+H]⁺) m/z calcd. for C₁₁H₂₂NO₄ 232.1549; found 232.1544.

1.5. (±)-*cis*-1-Benzoyl-4-(hydroxymethyl)piperidin-3-ol (7).

To a solution of **5** (360 mg, 2.7 mmol) and Et₃N (1.56 mL, 11.2 mmol) in DMF (7 mL), was added benzoyl chloride (357 μ L, 3.08 mmol) under nitrogen atmosphere. The mixture was stirred overnight at 80°C. The reaction mixture was diluted with brine (10 mL) and extracted with EtOAc (4 x 15 mL). The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. Purification by silica gel chromatography (CH₂Cl₂ / MeOH, 99:1) gave **7** as a brown oil (370 mg, 56%). ¹H NMR (500 MHz, CD₃OD, rotamers 40/60) δ 7.38-7.33 (m, 5H); 4.60-4.57 (m, 1H); 3.99 (br s, 0.4H); 3.74 (br s, 0.6H); 3.70-3.66 (m, 1H); 3.55-3.49 (m, 1H); 3.40-3.36 (m, 1H); 3.13-3.10 (dd, ²J=14.3 Hz, ³J=1.08 Hz, 0.6H); 2.99-2.90 (m, 0.4H); 2.86-2.83 (m, 0.4H); 2.75-2.74 (m, 0.6H); 1.75-1.71 (m, 1H); 1.55-1.49 (m, 1.6H); 1.40-1.30 (m, 0.4H). ¹³C NMR (125 MHz, DMSO-d₆) δ 173.8; 137.5 and 137.3; 130.9 and 130.8; 129.7 and 129.5; 128.6; 127.7; 66.1 and 66.0; 64.3 and 64.3; 55.4; 43.8; 43.4; 24.3; 23.5. $\nu_{\max}/\text{cm}^{-1}$ 3351, 2920, 1596, 1442, 1084. MS (ESI) m/z 236 ([M+H]⁺, 70); 218 (33); 114 (25); 105 (100). HRMS (ESI, [M+H]⁺) m/z calcd. for C₁₃H₁₈NO₃ 236.1287; found 236.1294.

1.6. (±)-*cis*-1-Butyl-4-(hydroxymethyl)piperidin-3-ol (8).

To a solution of **5** (147 mg, 1.12 mmol) in anhydrous DMF (2 mL) was added, *n*-butyl bromide (184 mg, 1.34 mmol) and potassium carbonate (619 mg, 4.47 mmol). The reaction mixture was stirred overnight at 70°C. After cooling to room temperature, water was added (3 mL) and the reaction mixture was extracted with EtOAc (3 x 3 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure to give **8** (115 mg, 55%) as a brown solid. mp: 101-103°C. ¹H NMR (400 MHz, CDCl₃) δ 3.88 (s, 1H); 3.66 (dd, ³J=4 Hz, ²J=10.8 Hz, 1H); 3.60 (dd, ³J=5.8 Hz, ²J=10.8 Hz, 1H); 2.89-2.81 (m, 2H); 2.30-2.24 (m, 2H); 2.02 (dd, ²J=11.4 Hz, ³J=1.2 Hz, 1H); 1.93-1.88 (m, 1H); 1.75-1.65 (m, 1H); 1.44-1.21 (m, 6H); 0.84 (t, ³J=7.2 Hz, 3H). ¹³C NMR (100.6 MHz, CDCl₃) δ 67.2; 65.2; 59.6; 57.7; 53.1; 41.2; 28.6; 22.6; 20.5; 13.9. $\nu_{\max}/\text{cm}^{-1}$ 3351, 2929, 1029. HRMS (ESI, [M+H]⁺) m/z calcd. for C₁₀H₂₂NO₂ 188.1651; found 188.1644.

1.7. (±)-*cis-tert*-Butyl 4-(trityloxymethyl)piperidin-3-ol-1-yl carboxylate (9).

To a solution of **6** (281 mg, 1.21 mmol) in anhydrous pyridine (6.5 mL) was added, triphenylmethyl chloride (400 mg, 1.44 mmol) and a catalytic amount of DMAP. The reaction mixture was heated at 110 °C for 10 h. After cooling to room temperature, water was added (5

mL) and the reaction mixture was extracted with EtOAc (4 x 5 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. Purification by silica gel chromatography (9/1, heptane/EtOAc) gave **6** (281 mg, 1.21 mmol) as a white solid (460 mg, 80%). mp: 139-141°C. ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.34 (m, 6H); 7.32-7.13 (m, 9H); 4.02-3.94 (m, 3H); 3.16-3.12 (m, 1H); 3.06-3.02 (m, 1H); 2.80-2.77 (m, 1H); 2.67-2.61 (m, 1H); 2.01 (br s, 1H); 1.73-1.69 (m, 1H); 1.59-1.53 (m, 1H); 1.37-1.35 (m, 10H). ¹³C NMR (100.6 MHz, CDCl₃) δ 155.9; 143.9; 128.6; 127.9; 127.0; 86.7; 79.7; 66.3; 64.9; 50.2; 43.4; 40.7; 28.4; 23.2. $\nu_{\text{max}}/\text{cm}^{-1}$ 3461, 2978, 1665, 1434, 1166, 1064. HRMS (ESI, [M+H]⁺) m/z calcd. for C₃₀H₃₅NO₄Na 496.2464; found 496.2471.

1.8. (±)-*cis*-1-Benzoyl-4-(trityloxymethyl)piperidin-3-ol (**10**).

Following the procedure for the preparation of **9**, the compound **10** was obtained from **7** (442 mg, 1.88 mmol) as a brown oil (640 mg, 71%). ¹H NMR (500 MHz, CD₃OD, rotamers) δ 7.34-7.10 (m, 20 H); 4.59-4.52 (m, 1H); 4.07 (s, 0.5H); 3.83 (s, 0.5H); 3.66-3.64 (m, 1H); 3.20-3.08 (m, 1.5H); 2.97-2.96 (m, 0.5H); 2.90-2.84 (m, 1.5H); 2.73-2.72 (m, 0.5H); 1.88-1.86 (m, 1H); 1.49-1.18 (m, 3H). ¹³C NMR (125 MHz, CD₃OD, rotamers) δ 173.7 and 173.5; 145.6; 137.5 and 137.3; 130.8 and 130.7; 129.9; 129.6 and 129.5; 128.8 and 128.6; 128.1 and 127.8; 87.6; 66.3 and 66.2; 65.8 and 65.7; 55.5; 43.4; 42.2 and 42.1; 24.8; 24.1 and 24.0. $\nu_{\text{max}}/\text{cm}^{-1}$ 3428, 1052, 1024. MS (ESI) m/z 478 ([M+H]⁺, 25); 243 (100). HRMS (ESI, [M+H]⁺) m/z calcd. for C₃₂H₃₂NO₃ 478.2382; found 478.2369.

1.9. (±)-*cis*-1-Butyl-4-(trityloxymethyl)piperidin-3-ol (**11**).

Following the procedure for the preparation of **9**, the compound **11** was obtained from **8** (100 mg, 0.53 mmol) as a brown oil (130 mg, 57%). ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, ³J=1.1 Hz, 6H); 7.32-7.23 (m, 9H); 3.97 (s, 1H); 3.26-3.22 (m, 1H); 3.26-3.22 (m, 1H); 3.04-2.98 (m, 2H); 2.90-2.84 (m, 1H); 2.39-2.33 (m, 2H); 2.13-2.10 (m, 1H); 2.03-1.94 (m, 1H); 1.68-1.64 (m, 1H); 1.57-1.34 (m, 6H); 0.92 (t, ³J=7.2 Hz, 3H). ¹³C NMR (100.6 MHz, CDCl₃) δ 144.3; 128.7; 127.7; 126.9; 86.4; 65.9; 65.0; 59.7; 57.8; 53.3; 40.9; 28.9; 23.9; 20.5; 14.0. $\nu_{\text{max}}/\text{cm}^{-1}$ 2929, 1447, 1099, 1065. MS (ESI) m/z 430 ([M+H]⁺, 11); 243 (100). HRMS (ESI, [M+H]⁺) m/z calcd. for C₂₉H₃₆NO₂ 430.2746; found 430.2751.

1.10. (±)-*cis*-1-Benzyl-4-(trityloxymethyl)piperidin-3-ol (**12**).

Following the procedure for the preparation of **9**, the compound **12** was obtained from **4** (200 mg, 0.9 mmol) as a white powder (256 mg, 61%). mp: 175-177°C. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (d, ³J=1.1 Hz, 6H); 7.23-7.12 (m, 14H); 3.89 (s, 1H); 3.45 (s, 2H); 3.15 (dd, ²J=8.8 Hz, ³J=7.56 Hz, 1H); 2.93-2.90 (m, 2H); 2.79-2.76 (m, 1H); 2.67 (br s, 1H); 2.11-2.09 (m, 1H); 1.97-1.90 (m, 1H); 1.61-1.58 (m, 1H); 1.46-1.39 (m, 2H). ¹³C NMR (100.6 MHz, CDCl₃) δ 144.3; 129.2; 128.7; 128.4; 127.7; 127.4; 126.9; 86.3; 65.8; 64.8; 62.5; 59.5; 52.9; 40.8; 23.6. $\nu_{\text{max}}/\text{cm}^{-1}$ 3020, 2910, 1447, 1072. HRMS (ESI, [M+H]⁺) m/z calcd. for C₃₂H₃₄NO₂ 464.2590; found 464.2597.

1.11. (±)-*cis-tert*-Butyl 4-(trityloxymethyl)-3-(methylsulfonyl) oxypiperidin-1-yl carboxylate (**13**).

To a solution of **9** (265 mg, 0.56 mmol) in dry pyridine (6 mL), was added silver trifluoromethanesulfonate (285 mg, 1.1 mmol) under nitrogen atmosphere at 0°C, followed by the addition of methanesulfonyl chloride (202 mg, 1.1 mmol). The reaction mixture was stirred at 0°C for 1 h, then further 2 h at room temperature. The reaction mixture was diluted with water (6 mL) and extracted with EtOAc (4 x 8 mL). The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. Purification by silica gel chromatography (CH₂Cl₂ / MeOH, 98:2) gave **13** as a white solid (255 mg, 82%). mp= 129-

131°C. ^1H NMR (400 MHz, CDCl_3) δ 7.32-7.17 (m, 15 H); 5.10-4.86 (m, 1H); 4.56-4.51 (m, 1H); 4.21-4.19 (m, 1H); 3.10-2.86 (m, 4H); 2.56 (s, 3H); 1.93-1.90 (m, 1H); 1.40-1.37 (m, 11H). $\nu_{\text{max}}/\text{cm}^{-1}$ 2930, 1681, 1445, 1174, 1067. HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{31}\text{H}_{37}\text{NO}_6\text{SNa}$ 574.2239; found 574.2233 HPLC purity: H_2O / MeCN ; 80:20; t_{R} : 9.5 min.

1.12. (\pm)-*cis*-1-Benzoyl-4-(trityloxymethyl)-3-(methylsulfonyl) oxypiperidine (14).

Following the procedure for the preparation of **13**, the compound **14** was obtained from **10** (200 mg, 0.42 mmol) as a yellow viscous oil (220 mg, 94%). ^1H NMR (400 MHz, CD_3OD , rotamers) δ 7.43-7.24 (m, 20 H); 5.18-5.07 (m, 1H); 4.76-4.65 (m, 0.5H); 4.11-4.08 (m, 0.5H); 3.73-3.70 (m, 0.5H); 3.43-3.39 (m, 0.5H); 3.15-2.57 (m, 7H); 2.20-2.15 (m, 1H); 1.62-1.43 (m, 2H). $\nu_{\text{max}}/\text{cm}^{-1}$ 3016, 2931, 1599, 1444, 1170, 1077. HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{33}\text{H}_{33}\text{NO}_5\text{SNa}$ 578.1977; found 578.1968. HPLC purity: H_2O / MeCN ; 80:20; t_{R} : 5.8 min.

1.13. (\pm)-*cis*-1-Butyl-4-(trityloxymethyl)-3-(methylsulfonyl)oxypiperidine (15).

Following the procedure for the preparation of **13**, the compound **15** was obtained from **11** (120 mg, 0.27 mmol) as a brown viscous oil (93 mg, 65%). ^1H NMR (400 MHz, CDCl_3) δ 7.34-7.32 (m, 6H); 7.25-7.17 (m, 9H); 4.97 (br s, 1H); 3.29-3.26 (m, 1H); 3.14-2.99 (m, 2H); 2.84-2.82 (m, 1H); 2.66 (s, 3H); 2.32-2.20 (m, 2H); 2.10-2.03 (m, 1H); 1.94-1.92 (m, 1H); 1.78-1.76 (m, 1H); 1.55-1.34 (m, 4H); 1.25-1.20 (m, 2H); 0.82 (t, $^3J=7.3$ Hz, 3H). $\nu_{\text{max}}/\text{cm}^{-1}$ 2961, 1448, 1153, 1066, 1037. MS (ESI) m/z 508 ($[\text{M}+\text{H}]^+$, 3); 430 (35); 243 (100). HPLC purity: H_2O / MeCN / TFA; 50:50:0.1; t_{R} : 10.8 min.

1.14. (\pm)-*cis*-1-Benzyl-4-(trityloxymethyl)-3-(methylsulfonyl)oxypiperidine (16).

Following the procedure for the preparation of **13**, the compound **16** was obtained from **12** (90 mg, 0.194 mmol) as a brown solid (103 mg, 98%). mp: 71-73°C. ^1H NMR (400 MHz, CDCl_3) δ 7.46-7.44 (m, 6H); 7.36-7.27 (m, 14H); 5.08 (br s, 1H); 3.59 (d, AB, $^2J=13.2$ Hz, 2H); 3.37-3.34 (m, 1H); 3.20-3.12 (m, 2H); 2.96-2.93 (m, 1H); 2.69 (s, 3H); 2.28-2.22 (m, 1H); 2.15-2.09 (m, 1H); 1.90-1.88 (m, 1H); 1.63-1.47 (m, 2H). ^{13}C NMR (100.6 MHz, CDCl_3) δ 143.8; 137.7; 129.1; 128.6; 128.2; 127.9; 127.2; 127.1; 86.8; 63.6; 62.5; 56.6; 53.4; 52.4; 40.2; 38.6; 23.7. $\nu_{\text{max}}/\text{cm}^{-1}$ 3055, 1448, 1173, 1038. MS (ESI) m/z 542 ($[\text{M}+\text{H}]^+$, 2); 464 (6); 243 (100). HPLC purity: H_2O / MeCN / TFA; 50:50:0.1; t_{R} : 12.4 min.

1.15. (\pm)-*cis-tert*-Butyl 1-[3-fluoro-4-(hydroxymethyl)piperidin-1-yl] carboxylate (*cis*-17) and (\pm)-*trans-tert*-butyl 1-[3-fluoro-4-(hydroxymethyl)piperidin-1-yl] carboxylate (*trans*-17).

A solution of 9-BBN (0.5 M in THF, 44.65 mL, 22.32 mmol) was added under nitrogen atmosphere to a solution of *tert*-butyl 1-[3-fluoro-4-methylenepiperidin-1-yl] carboxylate^a (3.2 g, 14.88 mmol) in THF (55 mL). The resulting solution was refluxed for 2 h. After cooling to 0°C, NaOH 3N (25 mL) was added and the mixture was stirred for 5 min. Then, H_2O_2 (25 mL) was added and the stirring was hold for 10 min. The reaction was quenched with water (50 mL) and the mixture was extracted with CH_2Cl_2 (3 x 50 mL). The combined organic layers were dried over MgSO_4 and concentrated under reduced pressure. Purification by silica gel chromatography (CH_2Cl_2 / AcOEt , 9:1) permitted to obtain *cis*-**17** (1.7 g, 49%) and *trans*-**17** (1.5 g, 43%) as colorless oils. *Cis*-**17**: ^1H NMR δ (400 MHz, CDCl_3) 4.74 (d, $^2J_{\text{H-F}}=48$ Hz, 1H); 4.36-4.04 (m, 2H); 3.67-3.62 (m, 1H); 3.56-3.52 (m, 1H); 2.82-2.59 (m, 2H); 1.76-1.54 (m, 3H); 1.39 (s, 9H). ^{13}C NMR δ (100.6 MHz, CDCl_3) 155.2 (CO); 86.1 (d, $^1J_{\text{C-F}}$

$\text{F}=176$ Hz, CH); 79.8 (C); 63.2 (d, $^4J_{\text{C-F}}=3.3$ Hz, CH_2); 49.0 (CH_2); 42.6 (CH_2); 41.8 (d, $^3J_{\text{C-F}}=19.8$ Hz, CH); 28.4 (CH_3); 22.4 (CH_2). ^{19}F NMR δ (376.5 MHz, CDCl_3) -203.4. MSMS (ESI) m/z 234 ($[\text{M}+\text{H}]^+$, 45); 178 (100). HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{11}\text{H}_{21}\text{FNO}_3$ 234.1505, found 234.1517. HPLC purity: H_2O / MeCN; 60:40; t_{R} : 8.7 min. *Trans*-**17**: ^1H NMR δ (400 MHz, CDCl_3) 4.39-4.21 (m, 2H); 3.97-3.95 (m, 1H); 3.70 (ABX, dd, $^3J=4.3$ Hz, $^2J=10.8$ Hz, 1H); 3.60 (ABX, dd, $^3J=5.2$ Hz, $^2J=10.8$ Hz, 1H); 2.68-2.62 (m, 2H); 1.77-1.69 (m, 2H); 1.38-1.25 (m, 10H). ^{13}C NMR δ (100.6 MHz, CDCl_3) 154.5 (CO); 88.0 (d, $^1J_{\text{C-F}}=176$ Hz, CH); 80.2 (C); 63.3 (d, $^4J_{\text{C-F}}=2.2$ Hz, CH_2); 48.0 (CH_2); 44.0 (d, $^3J_{\text{C-F}}=16$ Hz, CH); 41.0 (CH_2); 28.5 (CH_3); 26.2 (CH_2). ^{19}F NMR δ (376.5 MHz, CDCl_3) -186.8 (d, $^2J_{\text{H-F}}=49$ Hz). HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{11}\text{H}_{21}\text{FNO}_3$ 234.1505, found 234.1510. HPLC purity: H_2O / MeCN; 60:40; t_{R} : 10.7 min.

1.16. (\pm)-cis-3-fluoro-4-(hydroxymethyl)piperidine hydrochloride (*cis*-18**).**

Following the procedure for the preparation of *trans*-**18**, the compound *cis*-**18** was obtained from *cis*-**17** (240 mg, 1.03 mmol) as a yellow oil (174 mg, 99%). ^1H NMR (400 MHz, CD_3OD) δ 4.76 (d, $^2J_{\text{H-F}}=49.6$ Hz, 1H); 3.61 (ABX, dd, $^3J=8.4$ Hz, $^2J=10.8$ Hz, 1H); 3.46-3.42 (m, 1H); 3.27-3.20 (m, 1H); 3.09-3.04 (m, 1H); 2.80-2.76 (dd, $^2J=14.3$ Hz, $^3J=1.08$ Hz, 1H); 2.70-2.59 (m, 1H); 1.86-1.71 (m, 1H); 1.53-1.44 (m, 2H). ^{13}C NMR (100.6 MHz, CD_3OD) δ 87.5 (d, $^1J_{\text{C-F}}=171.3$ Hz); 63.8 (d, $^4J_{\text{C-F}}=3.5$ Hz); 50.2 (d, $^3J_{\text{C-F}}=21$ Hz); 45.8; 42.9 (d, $^3J_{\text{C-F}}=19.7$ Hz); 24.8. ^{19}F NMR (376.5 MHz, CDCl_3) δ -205.8. MS (ESI) m/z 134 ($[\text{M}+\text{H}]^+$, 100); 116 (100); 114 (37); 96 (66). HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_6\text{H}_{13}\text{FNO}$ 134.0981; found 134.0986.

1.17. (\pm)-trans-3-fluoro-4-(hydroxymethyl)piperidine hydrochloride (*trans*-18**).**

HCl gas was bubbled through a solution of *trans*-**17** (540 mg, 2.31 mmol) in EtOAc (3 mL) for about 45 min. The solvent was then removed under reduced pressure and the chlorhydrate *trans*-**18** was obtained as a yellow oil (390 mg, 99%). ^1H NMR (400 MHz, CD_3OD) δ 4.93-4.75 (m, 1H); 3.72 (d, $^3J=4.8$ Hz, 2H); 3.61-3.52 (m, 1H); 3.37-3.32 (m, 1H); 3.26-3.19 (m, 1H); 3.13-3.06 (m, 1H); 2.17-2.06 (m, 2H); 1.82-1.78 (m, 1H). ^{13}C NMR (100.6 MHz, CD_3OD) δ 86.0 (d, $^1J_{\text{C-F}}=173.6$ Hz); 61.4 (d, $^4J_{\text{C-F}}=6$ Hz); 45.9 (d, $^3J_{\text{C-F}}=28.4$ Hz); 43.1; 41.5 (d, $^3J_{\text{C-F}}=18.4$ Hz); 22.9 (d, $^4J_{\text{C-F}}=5.4$ Hz). ^{19}F NMR (376.5 MHz, CDCl_3) δ -189.3 (d, $^2J_{\text{H-F}}=169.3$ Hz). $\nu_{\text{max}}/\text{cm}^{-1}$ 3363, 1042. HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_6\text{H}_{13}\text{FNO}$ 134.0981; found 134.0986.

1.18. (\pm)-cis-1-Benzyl-3-fluoro-4-(hydroxymethyl)piperidine (*cis*-19**).**

To a solution of *cis*-**18** (1.2 g, 7.11 mmol), Et_3N (4 mL, 28.44 mmol) in DMF (15 mL), was added benzyl bromide (1.01 mL, 8.53 mmol). The reaction mixture was stirred overnight at 80°C. After cooling to RT, the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers were dried over MgSO_4 , filtered and concentrated under reduced pressure. Purification by silica gel chromatography (CH_2Cl_2 / MeOH, 98:2) led to *cis*-**19** (1.2 g, 73%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.37-7.29 (m, 5H); 4.86 (d, $^2J_{\text{H-F}}=48$ Hz, 1H); 3.79 (ABX, dd, $^3J=7.7$ Hz, $^2J=10.7$ Hz, 1H); 3.70-3.30 (m, 4H); 3.30-3.23 (m, 1H); 3.03-2.98 (m, 1H); 2.25-2.09 (m, 2H); 1.77-1.56 (m, 3H). ^{13}C NMR (100.6 MHz, CDCl_3) δ 137.7; 129.1; 128.2; 127.1; 87.1 (d, $^1J_{\text{C-F}}=174$ Hz); 63.5 (d, $^4J_{\text{C-F}}=4.4$ Hz); 62.72; 56.5 (d, $^3J_{\text{C-F}}=19.1$ Hz); 52.3; 41.4 (d, $^3J_{\text{C-F}}=19.4$ Hz); 23.2. ^{19}F NMR

(376.5 MHz, CDCl₃) δ -199.3. $\nu_{\max}/\text{cm}^{-1}$ 3318, 2921, 1453, 1070, 1012. HRMS (ESI, [M+H]⁺) m/z calcd. for C₁₃H₁₉FNO 224.1451; found 224.1459.

1.19. (±)-*trans*-1-Benzyl-3-fluoro-4-(hydroxymethyl)piperidine (*trans*-19).

Following the procedure for the preparation of *cis*-19, the compound *trans*-19 was obtained from *trans*-18 (114 mg, 0.86 mmol) as a yellow oil (110 mg, 57%). ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.30 (m, 5H); 4.61-4.44 (ddt, ²J_{H-F}=48 Hz, ³J=4.8 Hz, ³J=9.8 Hz, ³J=9.8 Hz, 1H); 3.86 (ABX, dd, ³J=4.8 Hz, ²J=10.8 Hz, 1H); 3.71 (ABX, dd, ³J=5.3 Hz, ²J=10.8 Hz, 1H); 3.64 (d, AB, ²J=13.2 Hz, 2H); 3.25-3.20 (m, 1H); 2.91-2.87 (m, 1H); 2.12-2.01 (m, 2H); 1.82-1.65 (m, 2H); 1.52-1.46 (m, 1H). ¹³C NMR (100.6 MHz, CDCl₃) δ 137.8; 129.0; 128.3; 127.2; 90.9 (d, ¹J_{C-F}=171.5 Hz); 64.4; 62.6; 57.0 (d, ³J_{C-F}=26 Hz); 52.4; 44.2 (d, ³J_{C-F}=16 Hz); 26.2 (d, ⁴J_{C-F}=9.1 Hz). ¹⁹F NMR (376.5 MHz, CDCl₃) δ -185.7 (d, ²J_{H-F}=45 Hz). $\nu_{\max}/\text{cm}^{-1}$ 3318, 2921, 1453, 1070, 1012. HRMS (ESI, [M+H]⁺) m/z calcd. for C₁₃H₁₉FNO 224.1451; found 224.1459.

1.20. (±)-*cis*-1-Benzoyl-3-fluoro-4-(hydroxymethyl)piperidine (*cis*-20).

Following the procedure for the preparation of 7, the compound *cis*-20 was obtained from *cis*-18 (126 mg, 0.75 mmol) as a white solid (154 mg, 87%). mp: 178-180°C. ¹H NMR (400 MHz, CD₃OD, rotamers 60/40) δ 7.49-7.41 (m, 5H); 5.09-4.75 (m, 2H); 4.34-4.32 (m, 1H); 4.17-4.15 (m, 0.4H); 4.08-4.02 (m, 0.6H); 3.84-3.80 (m, 0.4H); 3.55-3.54 (m, 0.6H); 3.14-2.90 (m, 2H); 2.38-2.29 (m, 1H); 1.79-1.67 (m, 1.6H); 1.28-1.11 (m, 0.4H). ¹³C NMR (100.6 MHz, CD₃OD, rotamers) δ 167.7; 162.5; 134.3; 131.3 and 131.1; 130.5; 129.6; 128.4 and 127.9; 127.7 and 122.2; 88.3 (d, ¹J_{C-F}=171 Hz); 65.9; 52.3 (d, ³J_{C-F}=23 Hz); 42.7; 40.1 (d, ³J_{C-F}=20.1 Hz); 23.8. ¹⁹F NMR (376.5 MHz, CD₃OD) δ -204.7. $\nu_{\max}/\text{cm}^{-1}$ 3364, 2930, 1612, 1462, 1073, 1024.

1.21. (±)-*trans*-1-Benzoyl-3-fluoro-4-(hydroxymethyl)piperidine (*trans*-20).

Following the procedure for the preparation of 7, the compound *trans*-20 was obtained from *trans*-18 (261 mg, 1.55 mmol) as a brown oil (80 mg, 22%). ¹H NMR (500 MHz, CD₃OD, rotamers 55/45) δ 7.38-7.32 (m, 5H); 4.62-4.60 (m, 0.5H); 4.43-4.27 (m, 1.5H); 3.73-3.71 (m, 0.5H); 3.60-3.57 (m, 2.5H); 3.20-2.94 (m, 2H); 1.88-1.83 (m, 1.5H); 1.72-1.69 (m, 0.5H); 1.47-1.44 (m, 0.5H); 1.35-1.33 (m, 0.5H). ¹³C NMR (125.7 MHz, CD₃OD, rotamers) δ 172.9; 136.7; 131.3; 129.8; 127.9; 88.6 and 88.1 (d, ¹J_{C-F}=174 Hz); 62.0; 51.3 and 46.1 (d, ³J_{C-F}=29 Hz); 48.0 and 42.0; 45.2 and 44.6 (d, ³J_{C-F}=18 Hz); 27.6 and 26.1. ¹⁹F NMR (376.5 MHz, CDCl₃) δ -188.1. $\nu_{\max}/\text{cm}^{-1}$ 3364, 2930, 1612, 1462, 1073, 1024. HRMS (ESI, [M+H]⁺) m/z calcd. for C₁₃H₁₇FNO₂ 238.1243; found 238.1254.

1.22. (±)-*cis*-1-Butyl-3-fluoro-4-(hydroxymethyl)piperidine (*cis*-21).

Following the procedure for the preparation of 8, the compound *cis*-21 was obtained from *cis*-18 (174 mg, 1.03 mmol) as a brown oil (72 mg, 54%). ¹H NMR (400 MHz, CD₃OD) δ 4.9-4.8 (m, 1H); 3.63 (ABX, dd, ³J=7.9 Hz, ²J=10.8 Hz, 1H); 3.50-3.46 (m, 1H); 3.33-3.26 (m, 1H); 3.02-2.98 (m, 1H); 2.43-2.34 (m, 2H); 2.21-2.18 (m, 2H); 1.72-1.50 (m, 5H); 1.55-1.31 (dt, ³J=14.8 Hz, ³J=7.4 Hz, 2H); 0.96 (t, ³J=7.4 Hz, 3H). ¹³C NMR (100.6 MHz, CD₃OD) δ 87.8 (d, ¹J_{C-F}=174 Hz); 63.3; 59.5; 57.6; 53.9; 42.9 (d, ³J_{C-F}=19.1 Hz); 29.3; 24.0; 21.8; 14.3. ¹⁹F NMR (376.5 MHz, CD₃OD) δ -201.1. $\nu_{\max}/\text{cm}^{-1}$ 3347, 2935, 1029. HRMS (ESI, [M+H]⁺) m/z calcd. for C₁₀H₂₁FNO 190.1607; found 190.1599.

1.23. (±)-*trans*-1-Butyl-3-fluoro-4-(hydroxymethyl)piperidine (*trans*-21).

Following the procedure for the preparation of **8**, the compound *trans*-**21** was obtained from *trans*-**18** (194 mg, 1.15 mmol) as a brown oil (168 mg, 77%). ¹H NMR (400 MHz, CD₃OD) δ 4.40 (ddt, ²J_{H-F}=49 Hz, ³J=4.8 Hz, ³J=16.6 Hz, ³J=16.6 Hz, 1H); 4.27 (ABX, dd, ³J=3.6 Hz, ²J=11.1 Hz, 1H); 4.10 (ABX, dd, ³J=5.7 Hz, ²J=11.1 Hz, 1H); 3.23-3.20 (m, 1H); 2.91-2.88 (m, 1H); 2.44-2.42 (m, 2H); 2.07-1.98 (m, 2H); 1.84-1.82 (m, 2H); 1.55-1.31 (m, 5H); 0.96 (t, ³J=7.3 Hz, 3H). ¹³C NMR (100.6 MHz, CD₃OD) δ 89.5 (d, ¹J_{C-F}=174 Hz); 65.2; 59.1; 58.1 (d, ³J_{C-F}=26.1 Hz); 53.4; 42.6 (d, ³J_{C-F}=17.1 Hz); 29.7; 27.0 (d, ⁴J_{C-F}=8.3 Hz); 21.7; 14.3. ¹⁹F NMR (376.5 MHz, CDCl₃) δ -188.2 (d, ²J_{H-F}=52 Hz). ν_{max}/cm⁻¹ 3347, 2935, 1029. HRMS (ESI, [M+H]⁺) *m/z* calcd. for C₁₀H₂₁FNO 190.1607; found 190.1598.

1.24. (±)-cis-1-Benzyl-3-fluoro-4-(trityloxymethyl)piperidine (cis-22).

Following the procedure for the preparation of **9**, the compound *cis*-**22** was obtained from *cis*-**19** (25 mg, 0.11 mmol) as a brown oil (20 mg, 39%). ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, ³J=7.08 Hz, 6H); 7.32-7.22 (m, 14H); 4.92 (d, ²J_{H-F}=48.6 Hz, 1H); 3.46 (d, AB, ²J=13.2 Hz, 2H); 3.18-3.10 (m, 2H); 2.95-2.92 (m, 1H); 2.84-2.81 (m, 1H); 2.12-1.93 (m, 2H); 1.71-1.43 (m, 3H). ¹³C NMR (100.6 MHz, CDCl₃) δ 144.2; 137.7; 129.2; 128.7; 128.2; 127.8; 127.1; 126.9; 87.6 (d, ¹J_{C-F}=175.7 Hz); 86.4; 63.6 (d, ⁴J_{C-F}=3.7 Hz); 62.7; 56.6 (d, ³J_{C-F}=19.0 Hz); 52.5; 40.0 (d, ³J_{C-F}=19.6 Hz); 23.7. ¹⁹F NMR (376.5 MHz, CDCl₃) δ -198.7. HRMS (ESI, [M+H]⁺) *m/z* calcd. for C₃₂H₃₃NOF 466.2546; found 466.2531. HPLC purity: H₂O / MeCN / TFA; 50:50:0.1; t_R: 13.1 min.

1.25. (±)-trans-Benzyl 3-fluoro-4-(trityloxymethyl)piperidine (trans-22).

Following the procedure for the preparation of **9**, the compound *trans*-**22** was obtained from *trans*-**19** (88 mg, 0.37 mmol) as a colourless oil (70 mg, 40%). ¹H NMR (400 MHz, CDCl₃) δ 7.49-7.46 (m, 6H); 7.39-7.25 (m, 14H); 4.56 (ddt, ²J_{H-F}=49.3 Hz, ³J=4.8 Hz, ³J=9.8 Hz, ³J=9.8 Hz, 1H); 3.60 (d, AB, ²J=13.1 Hz, 2H); 3.33-3.30 (m, 1H); 3.19-1.15 (m, 2H); 2.87-2.84 (m, 1H); 2.08-1.93 (m, 3H); 1.85-1.72 (m, 1H); 1.61-1.59 (m, 1H). ¹³C NMR (100.6 MHz, CD₃OD) δ 145.5; 138.3; 130.6; 129.8; 129.3; 128.7; 128.5; 128.0; 89.7 (d, ¹J_{C-F}=173 Hz); 87.6; 63.8 (d, ⁴J_{C-F}=33.1 Hz); 58.0 (d, ³J_{C-F}=26.1 Hz); 54.8; 53.6; 43.9 (d, ³J_{C-F}=17.1 Hz); 27.8 (d, ⁴J_{C-F}=9 Hz). ¹⁹F NMR (376.5 MHz, CDCl₃) δ -185.8 (d, ²J_{H-F}=48.9 Hz). ν_{max}/cm⁻¹ 3028, 2922, 1447, 1178, 1076, 1015. HRMS (ESI, [M+H]⁺) *m/z* calcd. for C₃₂H₃₃NOF 466.2546; found 466.2538. HPLC purity: H₂O / MeCN / TFA; 50:50:0.1; t_R: 17.2 min.

1.26. (±)-cis-1-Benzoyl-3-fluoro-4-(trityloxymethyl)piperidine (cis-23).

Following the procedure for the preparation of **9**, the compound *cis*-**23** was obtained from *cis*-**20** (60 mg, 0.25 mmol) as a white solid (70 mg, 58%). mp: 49-51°C. ¹H NMR (400 MHz, CD₃OD, rotamers) δ 7.47-7.25 (m, 20 H); 5.17-4.71 (m, 2H); 4.06-3.72 (m, 1H); 3.76-2.84 (m, 4H); 2.13-2.05 (m, 1H); 1.61-1.47 (m, 2H). ¹³C NMR (100.6 MHz, CD₃OD, rotamers) δ 173.6 and 173.3; 145.6 and 145.4; 137.0 and 136.8; 131.0; 129.8 and 129.6; 128.9; 128.4 and 128.2; 127.8; 88.5 (d, ¹J_{C-F}=176 Hz); 87.8; 64.6; 52.5; 48.3 and 47.6; 46.9; 42.9; 41.4; 24.7 and 23.9. ¹⁹F NMR (376.5 MHz, CDCl₃) δ -203.9. ν_{max}/cm⁻¹ 3056, 2927, 1630, 1446, 1155, 1070. HRMS (ESI, [M + Na]⁺) calcd. for C₃₂H₃₀NO₂FNa 502.2158; found 502.2163. HPLC purity: H₂O / MeCN; 80:20; t_R: 7.9 min.

1.27. (±)-trans-1-Benzoyl-3-fluoro-4-(trityloxymethyl)piperidine (trans-23).

Following the procedure for the preparation of **9**, the compound *trans*-**23** was obtained from *trans*-**20** (146 mg, 0.61 mmol) as a white solid (189 mg, 64%). mp: 141-143°C. ¹H NMR (400

MHz, CDCl₃, rotamers) δ 7.47-7.25 (m, 20 H); 4.8-4.1 (m, 2H); 3.74-3.55 (m, 1H); 3.22-2.93 (m, 4H); 1.96-1.82 (m, 2H); 1.56-1.42 (m, 1H). ¹⁹F NMR (376.5 MHz, CDCl₃) δ -185.8. HRMS (ESI, [M+Na]⁺) m/z calcd. for C₃₂H₃₀NO₂FNa 502.2158; found 502.2162. HPLC purity: H₂O / MeCN; 80:20; t_R: 9.1 min.

1.28. (±)-*cis*-1-Butyl-3-fluoro-4-(trityloxymethyl)piperidine (*cis*-24).

Following the procedure for the preparation of 12, the compound *cis*-24 was obtained from *cis*-21 (45 mg, 0.23 mmol) as a brown oil (79 mg, 79%). ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, ³J=7.4 Hz, 6H); 7.23-7.12 (m, 9H); 4.86 (d, ²J_{H-F}=48.3 Hz, 1H); 3.21-2.15 (m, 2H); 2.97-2.86 (m, 2H); 2.35-2.25 (m, 2H); 2.05-1.93 (m, 1H); 1.65-1.47 (m, 1H); 1.46-1.39 (m, 3H); 1.26-1.18 (m, 4H); 0.83 (t, ³J=7.3 Hz, 3H). ¹³C NMR (100.6 MHz, CD₃OD) δ 145.4; 129.8; 129.3; 128.8; 128.6; 128.1; 88.0 (d, ¹J_{C-F}=173.4 Hz); 87.9; 64.6; 59.1; 57.0 (d, ³J_{C-F}=19.1 Hz); 53.6; 40.4 (d, ³J_{C-F}=20.1 Hz); 28.5; 23.7; 21.5; 14.2. ¹⁹F NMR (376.5 MHz, CDCl₃) δ -198.0. $\nu_{\max}/\text{cm}^{-1}$ 3058, 2929, 1447, 1077, 1019. HRMS (ESI, [M+H]⁺) m/z calcd. for C₂₉H₃₅NOF 432.2703; found 432.2690. HPLC purity: H₂O / MeCN / TFA; 50:50:0.1; t_R: 13.5 min.

1.29. (±)-*trans*-1-Butyl-3-fluoro-4-(trityloxymethyl)piperidine (*trans*-24).

Following the procedure for the preparation of 9, the compound *trans*-24 was obtained from *trans*-21 (160 mg, 0.84 mmol) as a brown oil (147 mg, 40%). ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, ³J=7.4 Hz, 6H); 7.36-7.25 (m, 9H); 4.56 (ddt, ²J_{H-F}=49.3 Hz, ³J=4.9 Hz, ³J=9.8 Hz, ³J=9.8 Hz, 1H); 3.32-3.18 (m, 3H); 2.90-2.87 (m, 1H); 2.43-2.41 (m, 2H); 2.0-1.94 (m, 2H); 1.77-1.70 (m, 1H); 1.64-1.50 (m, 4H); 1.39-1.35 (m, 2H); 0.97 (t, ³J=7.3 Hz, 3H). ¹³C NMR (100.6 MHz, CDCl₃) δ 144.2; 128.7; 127.7; 126.9; 89.4 (d, ¹J_{C-F}=173.4 Hz); 86.3; 63.2; 58.2; 57.4 (d, ³J_{C-F}=25.6 Hz); 52.9; 42.8 (d, ³J_{C-F}=16.6 Hz); 29.1; 27.1 (d, ⁴J_{C-F}=8.7 Hz); 20.7; 14.0. ¹⁹F NMR (376.5 MHz, CDCl₃) δ -185.6 (d, ²J_{H-F}=47.4 Hz). $\nu_{\max}/\text{cm}^{-1}$ 3058, 2929, 1447, 1077, 1019. HRMS (ESI, [M+H]⁺) m/z calcd. for C₂₉H₃₅NOF 432.2703; found 432.2690. HPLC purity: H₂O / MeCN / TFA; 50:50:0.1; t_R: 13.1 min.

1.30. (±)-*cis-tert*-Butyl-3-fluoro-4-(trityloxymethyl)piperidin-1-yl carboxylate (*cis*-25).

Following the procedure for the preparation of 12, the compound *cis*-25 was obtained from *cis*-17 (133 mg, 0.57 mmol) as a yellow oil (85 mg, 31%). ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.34 (m, 6H); 7.24-7.13 (m, 9H); 4.83 (d, ²J_{H-F}=48.0 Hz, 1H); 4.33-4.14 (m, 2H); 3.16-3.11 (m, 1H); 2.95-2.60 (m, 3H); 1.83-1.69 (m, 1H); 1.5-1.37 (m, 11H). ¹³C NMR (100.6 MHz, CDCl₃) δ 155.2; 144.0; 128.7; 127.8; 127.0; 86.5; 86.3 (d, ¹J_{C-F}=177.3 Hz); 79.7; 63.5; 54.4; 52.9; 40.4 (d, ³J_{C-F}=19.9 Hz); 28.4; 22.9. ¹⁹F NMR (376.5 MHz, CDCl₃) δ -202.7. $\nu_{\max}/\text{cm}^{-1}$ 3058, 2928, 1689, 1447, 1168, 1069. HRMS (ESI, [M+Na]⁺) m/z calcd. for C₃₀H₃₄FNO₃Na 498.2420; found 498. 2399. HPLC purity: H₂O / MeCN; 80:20; t_R: 13.5 min.

1.31. (±)-*trans-tert*-Butyl-3-fluoro-4-(trityloxymethyl)piperidin-1-yl carboxylate (*trans*-25).

Following the procedure for the preparation of 12, the compound *trans*-25 was obtained from *trans*-17 (180 mg, 0.77 mmol) as a yellow viscous oil (100 mg, 27%). ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.34 (m, 6H); 7.20-7.13 (m, 9H); 4.44-4.27 (m, 1H); 4.15 (br s, 1H); 3.86 (br s, 1H); 3.18-3.09 (m, 1H); 2.69-2.63 (m, 2H); 1.82-1.77 (m, 2H); 1.50-1.39 (m, 11H). ¹³C NMR (100.6 MHz, CDCl₃) δ 154.6; 144.0; 128.7; 127.8; 127.0; 87.7 (d, ¹J_{C-F}=177.3 Hz); 86.5; 80.1; 62.7 (d, ⁴J_{C-F}=2.4 Hz); 48.0; 44.0; 42.5 (d, ³J_{C-F}=19.9 Hz); 28.4; 24.9. ¹⁹F NMR (376.5 MHz,

CDCl_3) δ -186.5. HRMS (ESI, $[\text{M}+\text{Na}]^+$) m/z calcd. for $\text{C}_{30}\text{H}_{34}\text{FNO}_3\text{Na}$ 498. 2420; found 498.2407. HPLC purity: H_2O / MeCN ; 80:20; t_R : 18.9 min.

1.32. (\pm)-*cis*-*tert*-Butyl 1-[4-(pyrimidin-2-ylamino)methylpiperidin-3-ol-1-yl]carboxylate (*cis*-26).

A mixture of (\pm)-*cis*-*tert*-butyl 1-[4-(azidomethyl)piperidin-3-ol-1-yl]carboxylate^a (690 mg, 2.69 mmol) and 10% palladium on carbon (200 mg) in methanol (40 mL) was stirred under H_2 atmosphere (1.2 bars) at room temperature for 7 h. The reaction mixture was filtered off then concentrated to give the intermediate amine as a yellow oil (610 mg, 99%). The intermediate amine (305 mg, 1.32 mmol) was dissolved in *tert*-amyl alcohol (4 mL), then 2-chloro-pyrimidine (226 mg, 1.98 mmol) and *N,N*-di-*isopropylethylamine* (DIPEA) (2ml) were added under nitrogen atmosphere. The reaction mixture was stirred 48 hours at 90°C, then diluted with water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO_4 and concentrated under reduced pressure. Purification by silica gel chromatography (CH_2Cl_2 / MeOH , 99:1) afforded *cis*-26 as yellow crystals (210 mg, 51%). mp: 125-127°C. Elem. analysis found: C, 57.34; H, 8.30; N, 17.57% calcd. for $\text{C}_{15}\text{H}_{24}\text{N}_4\text{O}_3 \cdot 0.2\text{H}_2\text{O}$: C, 57.74; H, 7.88; N, 17.95%. ^1H NMR δ (400 MHz, CDCl_3) 8.18 (d, $^3J=4.8$ Hz, 2H); 6.46 (m, 1H); 4.20-4.10 (m, 2H); 3.70 (bs, 1H); 3.57-3.49 (m, 1H); 3.14-3.10 (m, 1H); 2.73-2.63 (m, 2H); 1.65-1.59 (m, 2H); 1.39 (s, 9H); 1.28-1.26 (m, 1H). ^{13}C NMR δ (100.6 MHz, CDCl_3) 162.7; 158.1; 154.6; 110.5; 79.4; 63.8; 49.6; 43.3; 43.2; 41.5; 28.4; 23.8. HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{15}\text{H}_{25}\text{N}_4\text{O}_3$ 309.1927, found 309.1924. HPLC purity: H_2O / MeCN ; 70:30; t_R : 9.8 min.

1.33. (\pm)-*trans*-*tert*-Butyl 1-[4-(pyrimidin-2-ylamino)methylpiperidin-3-ol-1-yl]carboxylate (*trans*-26).

Following the procedure for the preparation of *cis*-26, the compound *trans*-26 was obtained from (\pm)-*trans*-*tert*-butyl 1-[4-(azidomethyl)piperidin-3-ol-1-yl]carboxylate^a (670 mg, 2.6 mmol) as yellow crystals (495 mg, 61%). mp: 114-116°C. ^1H NMR δ (400 MHz, CDCl_3) 8.18 (d, $^3J=4.8$ Hz, 2H); 6.50 (t, $^3J=4.8$ Hz, 2H); 4.17-3.94 (m, 3H); 3.19-3.05 (m, 2H); 2.59-2.46 (m, 2H); 1.55-1.39 (m, 12H). ^{13}C NMR δ (100.6 MHz, CDCl_3) 162.8; 158.1; 154.6; 110.7; 79.7; 67.1; 49.1; 45.4; 43.2; 43.0; 28.4; 27.9. HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{15}\text{H}_{25}\text{N}_4\text{O}_3$ 309.1927, found 309.1919. HPLC purity: H_2O / MeCN ; 60:40; t_R : 5.1 min.

1.34. (\pm)-*cis*(*trans*-Phenylcyclopropyl)[4-(pyrimidin-2-ylamino)methylpiperidin-3-ol-1-yl]methanone (27).

HCl gas was bubbled through a solution of *cis*-26 (240 mg, 0.67 mmol) in EtOAc (3 mL) for 45 min. The reaction mixture was concentrated under reduced pressure and the crude amine hydrochloride was dissolved in dry DMF (4 mL) and Et_3N (187 μL , 1.34 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (155 mg, 0.80 mmol), 1-hydroxy-7-azabenzotriazole (110 mg, 0.80 mmol) and *trans*-2-phenylcyclopropane-1-carboxylic acid (131 mg, 0.80 mmol) were added. The reaction mixture was stirred overnight at 70°C. After cooling to RT, the reaction mixture was diluted with water (5 mL) and extracted with EtOAc (4 x 5 mL). The combined organic layers were dried over MgSO_4 , concentrated under reduced pressure and purified by chromatography on silica gel (CH_2Cl_2 / MeOH , 98:2) led to 27 as a yellow oil (160 mg, 68%). ^1H NMR (400 MHz, CDCl_3) δ 8.30 (d, $^3J=4.8$ Hz, 2H); 7.33-7.13 (m, 5H); 6.59 (t, $^3J=4.8$ Hz, 1H); 5.80-5.75 (m, 1H); 4.76-4.55 (m, 1H); 4.31-4.25 (m, 1H); 3.93-3.80

(m, 1H); 3.68-3.62 (m, 1H); 3.20-3.13 (m, 2H); 2.75-2.40 (m, 2H); 2.20-2.07 (m, 1H); 1.85-1.28 (m, 6H). $\nu_{\max}/\text{cm}^{-1}$ 3331, 2971, 1592, 1044. MS (ESI) m/z 353 ($[\text{M}+\text{H}]^+$, 96); 335 (100); 209 (80); 191 (100); 145 (43). HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{20}\text{H}_{25}\text{N}_4\text{O}_2$ 353.1978; found 353.1972.

1.35. (\pm)-*cis*-4-Methylbenzyl 1-[4-(pyrimidin-2-ylamino)methylpiperidin-3-ol-1-yl]carboxylate (*cis*-28).

HCl gas was bubbled through a solution of *cis*-26 (560 mg, 1.81 mmol) in EtOAc (3 mL) for about 45 min. The mixture was then concentrated under reduced pressure and the crude amine hydrochloride was dissolved in dry DMF (5 mL). DIPEA (710 mg, 5.43 mmol) was added and the resulting solution was stirred for 30 min. To a solution of *N,N'*-disuccinimidyl carbonate (926 mg, 3.62 mmol) in dry acetonitrile (10 mL), was added 4-methylbenzyl alcohol (441 mg, 3.54 mmol) in dry CH_2Cl_2 (10 mL) and a catalytic amount of DMAP. The reaction mixture was stirred overnight at room temperature. The solution was then added to the amine hydrochloride previously prepared and stirred for two days at room temperature. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (4 x 15 mL). The combined organic layers were dried over MgSO_4 , concentrated under reduced pressure and purified by chromatography on silica gel (CH_2Cl_2 / MeOH, 98:2) led to *cis*-28 as a yellow oil (466 mg, 72%). ^1H NMR δ (400 MHz, CDCl_3) 8.15 (d, $^3J=4.8$ Hz, 2H); 7.17 (d, $^3J=8$ Hz, 2H); 7.06 (d, $^3J=8$ Hz, 2H); 6.44 (t, $^3J=4.8$ Hz, 1H); 5.83 (bs, 1H); 5.15-4.98 (m, 2H); 4.30-4.20 (m, 2H); 3.73-3.66 (m, 1H); 3.53-3.47 (m, 1H); 3.12-3.11 (m, 1H); 2.76-2.69 (m, 2H); 2.25 (s, 3H); 1.65-1.64 (m, 2H); 1.27 (bs, 1H). ^{13}C NMR δ (100.6 MHz, CDCl_3) 162.7; 158.1; 156.2; 137.6; 134.0; 129.1; 128.0; 110.6; 67.0; 63.6; 49.7; 43.8; 43.2; 41.5; 23.7; 21.2. $\nu_{\max}/\text{cm}^{-1}$ 3247, 1681, 1368, 1223. MSMS (ESI) m/z 357 ($[\text{M}+\text{H}]^+$, 100); 313 (55); 295 (30); 105 (50). HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{19}\text{H}_{25}\text{N}_4\text{O}_3$ 357.1927, found 357.1928.

1.36. (\pm)-*trans*-4-Methylbenzyl 1-[4-(pyrimidin-2-ylamino)methylpiperidin-3-ol-1-yl]carboxylate (*trans*-28).

Following the procedure for the preparation of *cis*-28, the compound *trans*-28 was obtained from *trans*-26 (250 mg, 0.81 mmol) as a yellow oil (160 mg, 55%). ^1H NMR δ (400 MHz, CDCl_3) 8.30 (d, $^3J=4.8$ Hz, 2H); 7.27 (d, $^3J=8$ Hz, 2H); 7.18 (d, $^3J=8$ Hz, 2H); 6.60 (t, $^3J=4.8$ Hz, 1H); 5.62 (bs, 1H); 5.1 (bs, 2H); 4.15-4.08 (m, 3H); 3.28 (bs, 1H); 3.19-3.15 (m, 1H); 2.78-2.67 (m, 2H); 2.38 (s, 3H); 1.63-1.58 (m, 3H). ^{13}C NMR δ (100.6 MHz, CDCl_3) 162.8; 158.1; 155.2; 137.8; 133.6; 129.1; 128.1; 110.9; 67.1; 66.9; 49.2; 45.5; 43.7; 42.8; 27.8; 23.2. HRMS (ESI, $[\text{M}+\text{H}]^+$) m/z calcd. for $\text{C}_{19}\text{H}_{25}\text{N}_4\text{O}_3$ 357.1927, found 357.1920. HPLC purity: H_2O / MeCN; 60:40; t_R : 9.4 min.

1.37. (\pm)-*cis*(*trans*-Phenylcyclopropyl)[4-(pyrimidin-2-ylamino)methyl-3-(methylsulfonyl)oxypiperidine-1-yl]methanone (29).

To a solution of 27 (47 mg, 0.13 mmol) in dry pyridine (2 mL), was added silver trifluoromethanesulfonate (68 mg, 0.26 mmol) under nitrogen atmosphere at 0°C, followed by the addition of methanesulfonyl chloride (48 mg, 0.26 mmol). The reaction mixture was stirred at 0°C for 1 h, then further 2 h at room temperature. The reaction mixture was diluted with water (4 mL) and extracted with EtOAc (4 x 2 mL). The combined organic layers were dried over MgSO_4 and concentrated under reduced pressure. Purification by silica gel chromatography (CH_2Cl_2 / MeOH, 98:2) gave 29 as a yellow oil (53 mg, 92%). ^1H NMR (400

MHz, CDCl₃, rotamers) δ 8.19 (m, 2H); 7.33-7.13 (m, 5H); 6.59 (t, ³J=4.8 Hz, 1H); 5.63-5.57 (m, 1H); 5.0-4.96 (m, 1.5H); 4.72-4.70 (m, 0.5H); 4.57-4.51 (m, 0.5H); 4.14 (br s, 0.5H); 3.53-3.49 (m, 1H); 3.19-3.05 (m, 4H); 2.66-2.55 (m, 2H); 2.41-1.93 (m, 3H); 1.58-1.18 (m, 4H). $\nu_{\text{max}}/\text{cm}^{-1}$ 3426, 2930, 1586, 1455, 1168, 1077. MS (ESI) m/z 355 ([M+H]⁺, 12); 335 (100); 191 (10). HRMS (ESI, [M+H]⁺) m/z calcd. for C₂₁H₂₇N₄O₄S 431.1753; found 431.1768. HPLC purity: H₂O / MeOH; 55:45; t_R : 9.9 min.

1.38. (±)-*cis*-4-Methylbenzyl 1-[4-(pyrimidin-2-yl)aminomethyl-3-(methylsulfonyl)hydroxypiperidin-1-yl] carboxylate (*cis*-30).

To a solution of *cis*-**28** (85 mg, 0.238 mmol) in dry pyridine (2 mL), was added silver trifluoromethanesulfonate (123 mg, 0.47 mmol) under nitrogen atmosphere at 0°C, followed by the addition of methanesulfonyl chloride (87 mg, 1.03 mmol). The reaction mixture was stirred at 0°C for 1 h, then further 1 h at room temperature. The reaction mixture was diluted with water (2 mL) and extracted with EtOAc (4 x 3 mL). The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. Purification by silica gel chromatography (CH₂Cl₂ / MeOH, 98:2) gave *cis*-**30** as yellow crystals (73 mg, 70%). mp: 107-109°C. Elem. analysis found: C, 54.73; H, 6.18; N, 12.93% calcd. for C₂₀H₂₆N₄O₅S: C, 55.28; H, 6.03; N, 12.89%. ¹H NMR δ (400 MHz, CDCl₃) 8.18 (d, ³J=4.8 Hz, 2H); 7.18 (m, 2H); 7.10 (m, 2H); 6.45 (t, ³J=4.8 Hz, 1H); 5.65 (bs, 1H); 5.14-4.86 (m, 3H); 4.54-4.41 (m, 1H); 4.31-4.16 (m, 1H); 3.54-3.47 (m, 1H); 3.11 (bs, 1H); 2.97-2.66 (m, 5H); 2.27 (s, 3H); 2.11 (bs, 1H); 1.51-1.45 (m, 2H). ¹³C NMR δ (100.6 MHz, CDCl₃) 162.1; 158.1; 156.2; 138.0; 134.0; 129.1; 128.0; 110.8; 74.9; 67.3; 47.6; 43.5; 42.4; 38.7; 38.1; 23.7; 21.2. HRMS (ESI, [M+H]⁺) m/z calcd. for C₂₀H₂₇N₄O₅S 435.1702, found 435.1683. HPLC purity: H₂O / MeCN; 60:40; t_R : 10.4 min.

1.39. (±)-*trans*-4-Methylbenzyl 1-[4-(pyrimidin-2-ylamino)methyl-3-(methylsulfonyl)hydroxypiperidin-1-yl] carboxylate (*trans*-30).

Following the procedure for the preparation of *cis*-**30**, the compound *trans*-**30** was obtained from *trans*-**28** (50 mg, 0.14 mmol) as a yellow oil (60 mg, 98%). ¹H NMR δ (400 MHz, CDCl₃) 8.18 (d, ³J=4.8 Hz, 2H); 7.17 (d, ³J=8 Hz, 2H); 7.08 (d, ³J=8 Hz, 2H); 6.45 (t, ³J=4.8 Hz, 1H); 5.40 (bs, 1H); 5.01 (bs, 2H); 4.46-4.45 (m, 1H); 4.33-4.29 (m, 1H); 3.92 (bs, 1H); 3.69 (bs, 1H); 3.45-3.38 (m, 1H); 3.03-2.79 (m, 5H); 2.27 (s, 3H); 1.95-1.93 (m, 1H); 1.87-1.83 (m, 1H); 1.36-1.33 (m, 1H). $\nu_{\text{max}}/\text{cm}^{-1}$ 3272, 3023, 2923, 1695, 1367, 1170. MSMS (ESI) m/z 359 ([M+H]⁺, 100); 339 (10); 295 (45); 105 (50). HRMS (ESI, [M+H]⁺) m/z calcd. for C₂₀H₂₇N₄O₅S 435.1702, found 435.1696. HPLC purity: H₂O / MeCN; 60:40; t_R : 12.9 min.

1.40. (±)-*cis*-*tert*-Butyl 1-[4-(pyrimidin-2-yl)aminomethyl-3-(methylsulfonyl)oxypiperidin-1-yl] carboxylate (*cis*-31).

Following the procedure for the preparation of **16**, the compound **31** was obtained from **26** (160 mg, 0.51 mmol) as a brown viscous oil (168 mg, 97%). mp: 110-112°C. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, ³J=4.8 Hz, 2H); 6.46 (t, ³J=4.8 Hz, 1H); 4.9 (br s, 1H); 4.47 (m, 1H); 4.2 (m, 1H); 3.5 (m, 1H); 3.15 (m, 1H); 3.04 (br s, 3H); 2.73-2.63 (m, 2H); 2.12-2.07 (m, 1H); 1.5-1.39 (m, 11H). ¹³C NMR (100.6 MHz, CD₃OD) δ 163.3; 159.3; 156.6; 111.6; 81.0; 77.3; 48.1; 45.0; 43.7; 40.0; 38.2; 28.6; 24.9. $\nu_{\text{max}}/\text{cm}^{-1}$ 2940, 1676, 1352, 1160. HRMS (ESI, [M+H]⁺) m/z calcd. for C₁₆H₂₇N₄O₅S: 387.1702; found: 387.1716. HPLC purity: H₂O / MeOH; 60:40; t_R : 8.3 min.

1.41. (±)-*cis*-*tert*-Butyl 1-[3-fluoro-4-(pyrimidin-2-ylamino)methylpiperidin-1-yl]carboxylate (*cis*-32).

Following the procedure for the preparation of *cis*-26, the compound *cis*-32 was obtained from (±)-*cis*-*tert*-butyl 1-[3-fluoro-4-(azidomethyl)piperidin-1-yl]carboxylate^a (818 mg, 3.17 mmol) as a yellow solid (457 mg, 46%). mp: 131-133°C. ¹H NMR δ (400 MHz, CDCl₃) 8.20 (d, ³J=4.7 Hz, 2H); 6.46 (t, ³J=4.8 Hz, 1H); 5.76 (bs, 1H); 4.67 (d, ²J_{H-F}=48 Hz, 1H); 4.33-4.18 (m, 2H); 3.43-3.31 (m, 2H); 2.79-2.64 (m, 2H); 2.09-1.84 (m, 1H); 1.56-1.50 (m, 2H); 1.39 (s, 9H). ¹³C NMR δ (100.6 MHz, CDCl₃) 162.5; 158.1; 155.2; 110.7; 86.6 (d, ²J_{C-F}=176 Hz); 79.8; 48.2; 42.9; 42.7 (d, ⁴J_{C-F}=3.3 Hz); 38.7 (d, ³J_{C-F}=19.9 Hz); 28.4; 23.7. ¹⁹F NMR δ (376.5 MHz, CDCl₃) -203.2 (d, ²J_{H-F}=30 Hz). HPLC purity : H₂O / MeCN; 60:40; t_R: 15.4 min.

1.42. (±)-*trans*-*tert*-Butyl 1-[3-fluoro-4-(pyrimidin-2-ylamino)methylpiperidin-1-yl]carboxylate (*trans*-32).

Following the procedure for the preparation of *cis*-26, the compound *trans*-32 was obtained from (±)-*trans*-*tert*-butyl 1-[3-fluoro-4-(azidomethyl)piperidin-1-yl]carboxylate^a (789 mg, 3.06 mmol) as a yellow solid (574 mg, 60%). mp: 124-126°C. Elem. analysis found: C, 58.39; H, 8.08; N, 17.79% calcd. for C₁₅H₂₃FN₄O₂: C, 58.05; H, 7.47; N, 18.05%. ¹H NMR δ (400 MHz, CDCl₃) 8.20 (d, ³J=4.7 Hz, 2H); 6.46 (t, ³J=4.7 Hz, 1H); 5.43 (bs, 1H); 4.33-4.17 (m, 2H); 3.9 (bs, 1H); 3.63-3.42 (m, 2H); 2.73-2.63 (m, 2H); 1.92-1.78 (m, 2H); 1.38 (s, 9H); 1.33-1.25 (m, 1H). ¹³C NMR δ (100.6 MHz, CDCl₃) 162.5; 158.0; 154.4; 110.7; 90.1 (d, ²J_{C-F}=176 Hz); 80.1; 47.0; 43.1 (d, ⁴J_{C-F}=2.2 Hz); 43.0; 42.2 (d, ³J_{C-F}=16.6 Hz); 28.3; 27.2. ¹⁹F NMR δ (376.5 MHz, CDCl₃) -185.8 (d, ²J_{H-F}=48.8 Hz). HRMS (ESI, [M+H]⁺) *m/z* calcd. for C₁₅H₂₄FN₄O₂ 311.1883, found 311.1873. HPLC purity: H₂O / MeCN; 60:40; t_R: 12.7 min.

1.43. (±)-*trans*-(*trans*-Phenylcyclopropyl)[3-fluoro-4-(pyrimidin-2-ylamino)methylpiperidin-1-yl]methanone (33).

Following the procedure for the preparation of 27, the compound 33 was obtained from *trans*-32 (47 mg, 0.15 mmol) as a yellow oil (20 mg, 38%). ¹H NMR (400 MHz, CD₃OD) δ 8.25 (d, ³J=4.8 Hz, 2H); 7.29-7.12 (m, 5H); 6.59 (t, ³J=4.8 Hz, 1H); 4.48-4.01 (m, 3H); 3.72-3.69 (m, 1H); 3.45-3.01 (m, 3H); 2.38-2.36 (m, 1H); 2.18-2.10 (m, 2H); 1.96-1.82 (m, 1H); 1.54-1.53 (m, 1H); 1.35-1.33 (m, 2H). *v*_{max}/cm⁻¹ 3332, 2972, 1589, 1047. HRMS (ESI, [M+H]⁺) *m/z* calcd. for C₂₀H₂₄FN₄O: 355.1934; found : 355.1934. HPLC purity: H₂O / MeOH; 55:45; t_R: 12.5 min.

1.44. (±)-*cis*-4-Methylbenzyl 1-[3-fluoro-4-(pyrimidin-2-ylamino)methylpiperidin-1-yl]carboxylate (*cis*-3).

Following the procedure for the preparation of *cis*-28, the compound *cis*-3 was obtained from *cis*-32 (160 mg, 0.516 mmol) as a yellow solid (65 mg, 35%). mp: 131-133°C. ¹H NMR δ (400 MHz, CDCl₃) 8.18 (d, ³J=4.8 Hz, 2H); 7.17 (d, ³J=8.4 Hz, 2H); 7.08 (d, ³J=7.8 Hz, 2H); 6.45 (t, ³J=4.8 Hz, 1H); 5.77 (bs, 1H); 5.02-5.01 (m, 2H); 4.79-4.17 (m, 3H); 3.44-3.29 (m, 2H); 2.85-2.67 (m, 2H); 2.27 (s, 3H); 2.02-1.89 (m, 1H); 1.54 (bs, 2H). ¹⁹F NMR δ (376.5 MHz, CDCl₃) -203.1. HRMS (ESI, [M+H]⁺) *m/z* calcd. for C₁₉H₂₄FN₄O₂ 359.1883, found 359.1887. HPLC purity: H₂O / MeCN; 55:45; t_R: 12.6 min.








1.45. (±)-*trans*-4-Methylbenzyl 1-[3-fluoro-4-(pyrimidin-2-ylamino)methylpiperidin-1-yl]carboxylate (*trans*-3).

Following the procedure for the preparation of *cis*-**28**, the compound *trans*-**3** was obtained from *trans*-**32** (164 mg, 0.52 mmol) as a yellow oil (72 mg, 38%). Elem. analysis found C, 63.86; H=6.85%; N, 15.54 calcd. for C₁₉H₂₃FN₄O₂: C, 63.67; H, 6.47; N, 15.63%. ¹H NMR δ (400 MHz, CDCl₃) 8.18 (d, ³J=4.8 Hz, 2H); 7.18 (d, ³J=7.9 Hz, 2H); 7.09 (d, ³J=7.9 Hz, 2H); 6.44 (t, ³J=4.8 Hz, 1H); 5.5 (bs, 1H); 5.0 (s, 2H); 4.32-4.20 (m, 2H); 3.96 (bs, 1H); 3.63-3.57 (m, 1H); 3.47-3.40 (m, 1H); 2.82-2.70 (m, 2H); 2.27 (s, 3H); 1.93-1.79 (m, 2H); 1.26-1.23 (m, 1H). ¹³C NMR δ (100.6 MHz, CDCl₃) 162.5; 158.0; 155.1; 138.0; 133.4; 129.2; 128.2; 110.7; 89.8 (d, ²J_{C-F}=178 Hz); 67.4; 47.0 (d, ³J_{C-F}=29.9 Hz); 43.0; 42.1; 42.0; 27.0; 21.2. ¹⁹F NMR δ (376.5 MHz, CDCl₃) -185.8 (d, ²J_{H-F}=47.8 Hz). HRMS (ESI, [M+H]⁺) *m/z* calcd. for C₁₉H₂₄FN₄O₂ 359.1883, found 359.1874. HPLC purity: H₂O / MeCN; 55:45; *t*_R: 14.3 min.

^a R. Koudih, G. Gilbert, M. Dhilly, A. Abbas, L. Barré, D. Debruyne, and F. Sobrio, *Eur. J. Med. Chem.*, 2012, **53**, 408-415.


2. *In silico* calculated pharmacological properties

Software: Chemsilico Predictor, Chemsilico LLC, Tewksbury, MA, USA.

Ligand (reference)	CSLogD _{7.4} : clogD _{7.4}	CSPB: Protein binding (%)	CSBBB: Log (Brain / Blood)	Brain / Blood ratio
 3 (27, 21)	2.77 ± 1.03	69.2 ± 13.2	-0.35 ± 0.22	0.45
 33 (27)	2.19 ± 0.94	47.7 ± 14.9	0.18 ± 0.17	1.51
 (27)	2.74 ± 0.9	84.4 ± 9.1	-0.91 ± 0.25	0.12
 (10)	3.03 ± 0.86	58.8 ± 15.7	0.09 ± 0.17	1.23
 (10)	3.00 ± 0.87	76.5 ± 9.5	0.14 ± 0.2	1.38
 (10)	2.27 ± 0.91	64.9 ± 11.3	-0.68 ± 0.19	0.21
 (10)	2.46 ± 0.71	65.35 ± 10.1	-0.25 ± 0.16	0.56

3. NMR Spectra


Compound 4.



```

NAME          RAK11
EXPNO         10
PROCNO        1
Date_         20081120
Time          13.28
INSTRUM       spect
PROBHD        5 mm QNP 1H/13
PULPROG       zg30
TD            65536
SOLVENT       CDCl3
NS            16
DS            2
SWH           8223.685 Hz
FIDRES        0.125483 Hz
AQ            3.9846387 sec
RG            64
RG            64
DW            60.800 usec
DE            8.00 usec
TE            295.0 K
D1            1.00000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1            11.00 usec
PL1           -1.00 dB
PL1W          15.25798988 W
SFO1          400.1324710 MHz
SI            32768
SF            400.1300402 MHz
WDW            EM
SSB            0
GB            0
PC            1.00
  
```




NAME RAK11
EXPNO 20
PROCNO 1
Date_ 20081126
Time 6.14
INSTRUM spect
PROBHD 5 mm QNP 1H/13
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 1024
DS 2
SWH 26041.666 Hz
FIDRES 0.397364 Hz
AQ 1.2583412 sec
RG 2050
DW 19.200 usec
DE 8.00 usec
TE 295.0 K
D1 1.5000000 sec
D11 0.0300000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 8.30 usec
PL1 -2.00 dB
PL1W 58.36251068 W
SFO1 100.6238364 MHz


===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 100.00 usec
PL2 -1.00 dB
PL12 18.00 dB
PL13 20.00 dB
PL1W 15.25798988 W
PL12W 0.19208671 W
PL13W 0.12119852 W
SFO2 400.1316005 MHz
SI 131072
SF 100.6127690 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

Compound 5.



NAME RARI4 1-5
EXPNO 40
PROCNO 1
Date_ 20081204
Time_ 12.30
INSTRUM spect
PROBHD 5 mm QNP 1H/13
PULPROG zgpg30
TD 65536
SOLVENT MeOD
NS 16
DS 2
SWH 8223.685 Hz
FIDRES 0.125483 Hz
AQ 3.984637 sec
RG 12.7
DW 60.800 usec
DE 8.00 usec
TE 295.0 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 11.00 usec
PL1 -1.00 dB
PL1W 15.25798988 W
SFO1 400.1324710 MHz
SI 32768
SF 400.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




```
NAME RAK14 1-5
EXPNO 51
PROCNO 1
Date_ 20081207
Time 12.37
INSTRUM spect
PROBHD 5 mm QNP 1H/1
PULPROG zgpg30
TD 65536
SOLVENT MeOD
NS 1024
DS 2
SWH 26041.666 Hz
FIDRES 0.397364 Hz
AQ 1.2583412 sec
RG 2050
DM 19.200 usec
DE 8.00 usec
TE 295.0 K
D1 1.50000000 sec
D11 0.03000000 sec
TDO 1

===== CHANNEL f1 =====
NUC1 13C
P1 8.30 usec
PL1 -2.00 dB
PL1W 58.36251068 W
SFO1 100.6238364 MHz

===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 100.00 usec
PL2 -1.00 dB
PL12 18.00 dB
PL13 20.00 dB
PL2W 15.25798988 W
PL1W 0.19208671 W
PL13W 0.12119852 W
SFO2 400.1316005 MHz
SI 131072
SF 100.6126261 MHz
MDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40
```


Compound 6.




NAME	RAK89 140-220
EXPNO	30
PROCNO	1
Date_	20090619
Time	16.02
INSTRUM	5 mm QNP 1H/13
PROBHD	zg30
PULPROG	65536
TD	MeOD
SOLVENT	16
NS	2
DS	8223.685 Hz
SWH	0.128483 Hz
FIDRES	3.9846387 sec
AQ	161
RG	60.800 usec
DM	8.00 usec
DE	295.0 K
TE	1.00000000 sec
D1	1
TD0	1


CHANNEL f1	1H
NUC1	12.00 usec
P1	-1.00 dB
PL1	15.25798988 W
PL1W	400.1324710 MHz
SFO1	32768
SI	400.1300479 MHz
SE	EXM
WDW	0
SSB	0.30 Hz
LB	0
GB	1.00
PC	

RAK89 140-220
20090619
16.02



Compound 7.







NAME RAK309 74-98
EXPNO 31
PROCNO 1
Date_ 20110518
Time_ 19.28
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
TD 65536
SOLVENT MeOD
NS 1824
DS 2
SWH 31250.000 Hz
FIDRES 0.476837 Hz
AQ 1.0486259 sec
RG 1820
DW 16.000 usec
DE 8.00 usec
TE 279.0 K
D1 1.00000000 sec
D11 0.0300000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 10.50 usec
PL1 1.50 dB
PL1W 64.3203691 W
SFO1 125.7703648 MHz


===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 80.00 usec
PL2 1.00 dB
PL12 15.72 dB
PL13 15.72 dB
PL2W 19.77305031 W
PL12W 0.66691983 W
PL13W 0.66691983 W
SFO2 500.1316005 MHz
SI 131072
SF 125.7576104 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40


Compound 8.





Compound 9.







NAME RAK75 69-74
EXPNO 11
PROCNO 1
Date_ 20101031
Time 0.29
INSTRUM spect
PROBHD 5 mm QNP 1H/13
PULPROG zgpg30
TD 262130
SOLVENT CDCl3
NS 1024
DS 2
SWH 26041.666 Hz
FIDRES 0.397354 Hz
AQ 1.2582012 sec
RG 320
DM 19.200 usec
DE 8.00 usec
TE 292.6 K
D1 1.50000000 sec
D11 0.03000000 sec
TD0 1


CHANNEL f1 13C
NUC1 13C
P1 8.20 usec
PL1 -2.00 dB
PL1W 58.36251068 W
SFO1 100.6238364 MHz

CHANNEL f2 1H
CPDPRG2 waltz16
NUC2 1H
PCPD2 100.00 usec
P12 -1.00 dB
PL12 17.42 dB
PL13 15.25710642 dB
P12W 0.21953173 W
PL12W 0.21953173 W
PL13W 400.1316005 MHz
SFO2 400.1316005 MHz
SI 131072
SF 100.6127690 MHz
WDW EM
SSB 0 Hz
GB 0
PC 1.40


Compound 10.










Compound 12.







Compound *cis*-18.







Compound *trans*-18.





Compound *cis*-19.








NAME RAK405 50-60
EXPNO 22
PROCNO 1
Date_ 20110403
Time 18.45
INSTRUM spect
PROBHD 5 mm QNP 1H/13
PULPROG zgpg30
TD 26536
F2 25336
SOLVENT CDCl3
NS 1024
DS 2
SWH 26041.666 Hz
FIDRES 0.393364 Hz
AQ 1.2582050 sec
RG 2050
DM 19.200 usec
DE 8.00 usec
TE 295.2 K
D1 1.50000000 sec
D11 0.03000000 sec
TDO 1

CHANNEL F1 13C
NUC1 13C
P1 9.50 usec
PL1 -1.00 dB
PL1W 46.35898972 W
SFO1 100.628364 MHz

CHANNEL F2 1H
CPDPRG2 waltz16
NUC2 1H
PCPD2 100.00 usec
PL2 -5.00 dB
PL12 19.44 dB
PL13 19.44 dB
PL14 38.3261354 dB
PL15 0.13787873 W
PL1W 0.21953173 W
SFO2 400.136005 MHz
ST 131072
SF 100.6127690 MHz
WDW EX
SSB 0
GB 1.00 Hz
PC 1.40

Compound *trans*-19.







NAME RAK04 20-10
EXPNO 22
PROCNO 1
Date_ 20110403
Time 20.29
INSTRUM spect
PROBHD 5 mm QNP 1H/13
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 1024
DS 2
SWH 26041.666 Hz
FIDRES 0.392364 Hz
AQ 1.2582032 sec
RG 320
DM 19.200 usec
DE 8.00 usec
TE 295.2 K
D1 1.50000000 sec
D11 0.03000000 sec
TD0 1

CHANNEL F1 13C
NUC1 13C
P1 9.50 usec
PL1 -1.00 dB
PL1W 46.35989712 W
SFO1 100.628364 MHz

CHANNEL F2 1H
CPDPRG2 waltz16
NUC2 1H
PCPD2 100.00 usec
PL2 -5.00 dB
PL12 19.44 dB
PL13 19.44 dB
PL14 38.3241542 dB
PL15 19.44 dB
PL12W 0.11788873 W
PL13W 0.21953173 W
SFO2 400.1316005 MHz
SI 131072
SF 100.6127650 MHz
WDW EM
SSB 0 Hz
GB 1.00 Hz
PC 1.40

Compound *trans*-20.







NAME RA314-69-78
EXPNO 12
PROCNO 1
Date_ 20110506
Time 20.36
INSTRUM spect
PROBHD 5 mm PABBO30
PULPROG zgpg30
TD 65536
SOLVENT MeOD
NS 6144
DS 2
SWH 31250.000 Hz
F2 1044443.100 Hz
RG 1.0468258 sec
AQ 128
IN 16.000 usec
DE 8.00 usec
TE 278.2 K
D1 1.00000000 sec
D11 0.03000001 sec
TD0 1

CHANNEL f1
NUC1 13C
P1 10.50 usec
PL1 1.50 dB
PL1W 64.3203659 W
SFO1 125.7703648 MHz


CHANNEL f2
Waltz16
NUC2 1H
PCPD2 80.00 usec
F12 15.00 dB
F12W 15.77 dB
PL12 19.7730503 W
PL12W 0.66691983 W
PL13W 0.66691983 W
SFO2 500.1316005 MHz
SI 131072
SF 125.7576104 MHz
WDW 1
SSB 0
GB 1.00 Hz
PC 1.40


Compound *cis*-21.





Compound *trans*-21.





Compound 29.

